Nelfinavir: Difference between revisions
Jump to navigation
Jump to search
| Line 24: | Line 24: | ||
'''| [[Nelfinavir drug interactions|Drug Interactions]]''' | '''| [[Nelfinavir drug interactions|Drug Interactions]]''' | ||
'''| [[Nelfinavir overdosage|Overdosage]]''' | '''| [[Nelfinavir overdosage|Overdosage]]''' | ||
'''| [[Nelfinavir dosage and administration|Dosage and Administration]]''' | '''| [[Nelfinavir dosage and administration|Dosage and Administration]]''' | ||
'''| [[Nelfinavir how supplied|How Supplied]]''' | '''| [[Nelfinavir how supplied|How Supplied]]''' | ||
Revision as of 16:45, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Category
US Brand Names
VIRACEPT®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Nelfinavir is an inhibitor of the HIV-1 protease. Inhibition of the viral protease prevents cleavage of the gag and gag-pol polyprotein resulting in the production of immature, non-infectious virus.[1]
References
- ↑ "VIRACEPT (NELFINAVIR MESYLATE) TABLET, FILM COATED VIRACEPT (NELFINAVIR MESYLATE) POWDER [AGOURON PHARMACEUTICALS INC]". Text " accessdate" ignored (help)